Skip to main content


Latest articles

12-04-2022 | Diabetes | News | Article

Greatest SGLT2 inhibitor benefits found with poorer heart failure prognosis

A meta-analysis reveals that people with a poor heart failure prognosis stand to gain the most from sodium-glucose cotransporter SGLT2 inhibition, regardless of whether or not they have type 2 diabetes.

11-04-2022 | Diabetes | News | Article

Therapeutic inertia increasing in type 2 diabetes

The proportion of individuals receiving second-line therapy for diabetes has decreased over time despite worsening glycemic control over the same period, US study findings indicate.

08-04-2022 | Diabetes | News | Article

Within-class switch to semaglutide brings benefits in real-world cohort

Real-world data confirm glycated hemoglobin and weight benefits, albeit attenuated, for people with type 2 diabetes switching to injectable semaglutide from other GLP-1 receptor agonists.

08-04-2022 | Diabetes | News | Article

Pivotal study shows feasibility of extended-wear insulin infusion set

An extended-wear insulin infusion set, worn for up to 7 days, is more satisfactory to users than standard insulin infusion sets and does not adversely affect glycemic control, shows a study in people with type 1 diabetes.

07-04-2022 | Diabetes | News | Article

Mental illness no barrier to glucose control in type 2 diabetes

People with type 2 diabetes who have mental health conditions are just as likely as those who do not to achieve their blood glucose targets, report researchers.

04-04-2022 | Diabetes | News | Article

Phase 3 trial supports dapagliflozin in young people with type 2 diabetes

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.

04-04-2022 | Diabetes | News | Article

Ethnicity, deprivation tied to long-term GDM sequelae

Being in a minority ethnic group and having low socioeconomic status increase women’s risk for developing certain long-term health complications after a pregnancy affected by gestational diabetes, a study shows.

01-04-2022 | Diabetes | News | Article

CVD-focused SGLT2 inhibitor prescribing failing to take hold

The proven cardiovascular benefits of SGLT2 inhibitors has not led doctors to prioritize their use in people at high risk, show findings from UK general practice.

01-04-2022 | Diabetes | News | Article

Higher semaglutide dose approved in USA

Click through to read more on this announcement

31-03-2022 | Diabetes | News | Article

Flash UK: isCGM benefits hold up in setting of poor glycemic control

People with type 1 diabetes and poor glycemic control benefit from use of intermittently scanned continuous glucose monitoring versus self-monitored blood glucose, report the Flash UK investigators.

31-03-2022 | Diabetes | News | Article

Comorbidities strike earlier and more often in type 2 diabetes

People with type 2 diabetes develop other chronic conditions more frequently and around 5 years earlier than those without, say researchers.

30-03-2022 | Diabetes | News | Article

Continuity of care linked to reduced CVD risk among people with diabetes

Increased team-based continuity of care correlates with decreased risk for cardiovascular disease in people with type 2 diabetes, researchers report in Diabetes Care.

29-03-2022 | Diabetes | News | Article

Paternal metformin exposure linked to increased birth defect risk

The risk for a birth defect may be increased if the father is taking metformin around the time of spermatogenesis, say researchers.

29-03-2022 | Diabetes | News | Article

Best statins for non-HDL cholesterol reduction in diabetes revealed

Moderate- or high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin are the most effective statins for reducing non-high-density lipoprotein cholesterol levels in people with diabetes, study findings indicate.

28-03-2022 | Diabetes | News | Article

Diabetes treatment deintensification uncommon in nursing home residents

Less than a third of nursing home residents who meet the criteria for overtreatment of type 2 diabetes have their treatment deintensified, suggests an analysis of Veterans Affairs data.

24-03-2022 | Diabetes | News | Article

Studies flag potential post-COVID-19 type 2 diabetes risk

Two large cohort studies have demonstrated an increased likelihood of being diagnosed with type 2 diabetes in the months following SARS-CoV-2 infection.

22-03-2022 | Diabetes | News | Article

Residual beta-cell function protects nocturnal, postprandial glycemic control

Individuals with type 1 diabetes and residual β-cell function have better nocturnal and postprandial glycemic control than those with no β-cell function, UK study findings indicate.

21-03-2022 | Diabetes | News | Article

Poor beta-cell function blamed for type 2 diabetes in young lean Asian Indians

Type 2 diabetes in young, lean people is much more common in Asian Indians than in White Europeans, say researchers who found that genetically determined beta-cell function may be to blame.

18-03-2022 | Diabetes | News | Article

Weight gain and loss may both signal high cardiovascular risk in type 2 diabetes

The gain or loss of more than 5% bodyweight within a 2-year period is associated with an increased risk for major adverse cardiovascular events in people with type 2 diabetes, say researchers.

17-03-2022 | Diabetes | News | Article

Mini-dose glucagon better than glucose tablets for Ramadan hypoglycemia

Subcutaneous mini-dose glucagon reverses hypoglycemia more effectively than oral glucose tablets and helps adults with type 1 diabetes complete Ramadan fasts, shows a randomized crossover trial.